RAS proteins are among the most frequently mutated in solid tumors [1], and targeted therapies against the activating mutation KRAS G12C are clinically active for various solid tumors including non-small-cell lung (sotorasib [4] and adagrasib [5]) and pancreatic (sotorasib [6]) cancers. Here, KRAS is linked to cancer.